146 436

Cited 0 times in

Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis.

Authors
 Ha-young Lee  ;  Sang Joon Shin  ;  Hyo Song Kim  ;  Soo Jung Hong  ;  Jung Woo Han  ;  Seung Taek Lim  ;  Jae Kyung Roh  ;  Sun Young Rha 
Citation
 CANCER RESEARCH AND TREATMENT, Vol.44(1) : 43-49, 2012 
Journal Title
CANCER RESEARCH AND TREATMENT
ISSN
 1598-2998 
Issue Date
2012
Keywords
Docetaxel ; Gemcitabine ; Refractory soft-tissue sarcoma ; Weekly
Abstract
PURPOSE: The combination of gemcitabine and docetaxel (GD) is used to effectively treat patients with soft tissue sarcoma (STS). It is widely considered that the conventional doses used are too high for long term use and many patients must discontinue GD treatment due to its toxicity. Therefore, to determine the appropriate dose meeting acceptable efficacy results, while minimizing toxic side effects, we treated patients with a weekly infusion of GD (weekly GD).

MATERIALS AND METHODS: A total of 22 patients presenting a variety of STSs were treated at Yonsei Cancer Center. All patients had metastatic or recurrent cancer and had previously received doxorubicin and ifosfamide combination chemotherapy. In all cases, gemcitabine (1,000 mg/m(2)) and docetaxel (35 mg/m(2)) were administered intravenously on days 1 and 8 of a 21-day cycle. We retrospectively reviewed the medical records of these patients.

RESULTS: The response rate was 4.5%, with one patient diagnosed with leiomyosarcoma having a partial response, and the disease control rate was 40.9%. The median progression-free survival (PFS) duration was 2.7 months and the PFS was correlated with the treatment response to a weekly GD. The median overall survival (OS) duration was 7.8 months and the OS was correlated with histology. There was no significant difference in OS between patients who received weekly GD as a 2nd line chemotherapy and those who received 3rd line or more. Treatment was generally well tolerated.

CONCLUSION: Weekly GD was well tolerated and showed moderate efficacy, indicating that this could be a reasonable option as a salvage treatment for metastatic STS.
Files in This Item:
T201202925.pdf Download
DOI
22500160
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hyo Song(김효송) ORCID logo https://orcid.org/0000-0002-0625-9828
Roh, Jae Kyung(노재경)
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Lee, Ha Young(이하영)
Lim, Seung Taek(임승택)
Han, Jung Woo(한정우) ORCID logo https://orcid.org/0000-0001-8936-1205
Hong, Soo Jung(홍수정)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/89877
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links